

E J Crosbie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7316852/publications.pdf>

Version: 2024-02-01

123
papers

3,433
citations

147726
31
h-index

182361
51
g-index

126
all docs

126
docs citations

126
times ranked

3834
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in genetic technologies result in improved diagnosis of mismatch repair deficiency in colorectal and endometrial cancers. <i>Journal of Medical Genetics</i> , 2022, 59, 328-334.	1.5	7
2	Uptake and efficacy of bilateral risk reducing surgery in unaffected female <i>BRCA1</i> and <i>BRCA2</i> carriers. <i>Journal of Medical Genetics</i> , 2022, 59, 133-140.	1.5	11
3	Synchronous uterine and bladder cancers detected in urine and vaginal samples by cytology. <i>Diagnostic Cytopathology</i> , 2022, 50, .	0.5	3
4	The impact of obesity and bariatric surgery on the immune microenvironment of the endometrium. <i>International Journal of Obesity</i> , 2022, 46, 605-612.	1.6	20
5	Women's Risk Perceptions and Willingness to Engage in Risk-Reducing Interventions for the Prevention of Obesity-Related Endometrial Cancer. <i>International Journal of Women's Health</i> , 2022, Volume 14, 57-66.	1.1	6
6	<i>BRCA1/2</i> in non-mucinous epithelial ovarian cancer: tumour with or without germline testing?. <i>British Journal of Cancer</i> , 2022, 127, 163-167.	2.9	2
7	Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape. <i>Journal of Pathology</i> , 2022, 257, 340-351.	2.1	11
8	The Performance of HE4 Alone and in Combination with CA125 for the Detection of Ovarian Cancer in an Enriched Primary Care Population. <i>Cancers</i> , 2022, 14, 2124.	1.7	14
9	Development and evaluation of polygenic risk scores for prediction of endometrial cancer risk in European women. <i>Genetics in Medicine</i> , 2022, 24, 1847-1856.	1.1	6
10	The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2022, 151, 1626-1639.	2.3	8
11	Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer. <i>Cancers</i> , 2022, 14, 3306.	1.7	8
12	Assessment of mismatch repair deficiency in ovarian cancer. <i>Journal of Medical Genetics</i> , 2021, 58, 687-691.	1.5	13
13	PROgesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study. <i>Cancer Prevention Research</i> , 2021, 14, 263-274.	0.7	11
14	Specialist oncological surgery for removal of the ovaries and fallopian tubes in <i>BRCA1</i> and <i>BRCA2</i> pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels. <i>International Journal of Cancer</i> , 2021, 148, 1155-1163.	2.3	13
15	A mismatch in care: results of a United Kingdom-wide patient and clinician survey of gynaecological services for women with Lynch syndrome. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 728-736.	1.1	13
16	Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. <i>Genetics in Medicine</i> , 2021, 23, 705-712.	1.1	28
17	Lynch syndrome for the gynaecologist. <i>The Obstetrician and Gynaecologist</i> , 2021, 23, 9-20.	0.2	18
18	Impact of socioeconomic deprivation on endometrial cancer survival in the North West of England: a prospective database analysis. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1215-1224.	1.1	18

#	ARTICLE	IF	CITATIONS
19	European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender. <i>British Journal of Surgery</i> , 2021, 108, 484-498.	0.1	130
20	Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. <i>Journal of Medical Genetics</i> , 2021, 58, 217-226.	1.5	15
21	The Management of Peutz-Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline. <i>Journal of Clinical Medicine</i> , 2021, 10, 473.	1.0	65
22	Detecting endometrial cancer. <i>The Obstetrician and Gynaecologist</i> , 2021, 23, 103-112.	0.2	25
23	CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records. <i>British Journal of General Practice</i> , 2021, 71, e465-e472.	0.7	13
24	Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer. <i>Cancers</i> , 2021, 13, 718.	1.7	17
25	Diagnostic accuracy of cytology for the detection of endometrial cancer in urine and vaginal samples. <i>Nature Communications</i> , 2021, 12, 952.	5.8	35
26	Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1212-1220.	3.0	47
27	Could Ovarian Cancer Prediction Models Improve the Triage of Symptomatic Women in Primary Care? A Modelling Study Using Routinely Collected Data. <i>Cancers</i> , 2021, 13, 2886.	1.7	1
28	No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2856.	1.0	11
29	Comprehensive Library Generation for Identification and Quantification of Endometrial Cancer Protein Biomarkers in Cervico-Vaginal Fluid. <i>Cancers</i> , 2021, 13, 3804.	1.7	9
30	Eliminating Cervical Cancer: Progress and Challenges for High-income Countries. <i>Clinical Oncology</i> , 2021, 33, 550-559.	0.6	32
31	Developing Tests for Endometrial Cancer deTection (DETECT): protocol for a diagnostic accuracy study of urine and vaginal samples for the detection of endometrial cancer by cytology in women with postmenopausal bleeding. <i>BMJ Open</i> , 2021, 11, e050755.	0.8	7
32	Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium. <i>Cancer Prevention Research</i> , 2021, 14, 1041-1050.	0.7	27
33	Comparison of two immunoassays for the measurement of serum HE4 for ovarian cancer. <i>Practical Laboratory Medicine</i> , 2021, 26, e00235.	0.6	10
34	Histological and Somatic Mutational Profiles of Mismatch Repair Deficient Endometrial Tumours of Different Aetiologies. <i>Cancers</i> , 2021, 13, 4538.	1.7	8
35	HE4 as a Biomarker for Endometrial Cancer. <i>Cancers</i> , 2021, 13, 4764.	1.7	35
36	HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes. <i>Cancers</i> , 2021, 13, 44.	1.7	40

#	ARTICLE	IF	CITATIONS
37	Does Clinical and Biochemical Thyroid Dysfunction Impact on Endometrial Cancer Survival Outcomes? A Prospective Database Study. <i>Cancers</i> , 2021, 13, 5444.	1.7	6
38	EPV284/#238â€¦The early detection of vulvar cancer through self-examination (educate) study: what women and clinicians think. , 2021, , .		0
39	EPV128/#510â€¦Womb cancer risk awareness: developing tools to influence change. , 2021, , .		0
40	Epithelial ovarian cancer risk: A review of the current genetic landscape. <i>Clinical Genetics</i> , 2020, 97, 54-63.	1.0	31
41	Does the vaginal microbiome drive cervical carcinogenesis?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 181-181.	1.1	7
42	Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. <i>Genetics in Medicine</i> , 2020, 22, 15-25.	1.1	365
43	Endometrial cancer prevention in high-risk women. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 65, 66-78.	1.4	45
44	Hypoxia and hyperglycaemia determine why some endometrial tumours fail to respond to metformin. <i>British Journal of Cancer</i> , 2020, 122, 62-71.	2.9	22
45	Challenging the believed proportion of ovarian cancer attributable to BRCA2 versus BRCA1 pathogenic variants. <i>European Journal of Cancer</i> , 2020, 124, 88-90.	1.3	2
46	Detection of MCM5 as a novel non-invasive aid for the diagnosis of endometrial and ovarian tumours. <i>BMC Cancer</i> , 2020, 20, 1000.	1.1	19
47	Risk-Reducing Gynecological Surgery in Lynch Syndrome: Results of an International Survey from the Prospective Lynch Syndrome Database. <i>Journal of Clinical Medicine</i> , 2020, 9, 2290.	1.0	12
48	Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer. <i>Metabolites</i> , 2020, 10, 314.	1.3	32
49	The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study. <i>PLoS Medicine</i> , 2020, 17, e1003263.	3.9	58
50	Identifying Ovarian Cancer in Symptomatic Women: A Systematic Review of Clinical Tools. <i>Cancers</i> , 2020, 12, 3686.	1.7	12
51	Detecting Endometrial Cancer by Blood Spectroscopy: A Diagnostic Cross-Sectional Study. <i>Cancers</i> , 2020, 12, 1256.	1.7	32
52	Response to Benusiglio et al.. <i>Genetics in Medicine</i> , 2020, 22, 1424-1425.	1.1	1
53	Feasibility of Gynaecologist Led Lynch Syndrome Testing in Women with Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1842.	1.0	10
54	Research priority setting in womenâ€™s health: a systematic review. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2020, 127, 694-700.	1.1	23

#	ARTICLE	IF	CITATIONS
55	Authors' reply re: Mirena Coil is a suitable treatment of early-stage endometrial cancer in obese women: FOR or AGAINST?. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 1300-1301.	1.1	3
56	Cost-Effectiveness of the Manchester Approach to Identifying Lynch Syndrome in Women with Endometrial Cancer. Journal of Clinical Medicine, 2020, 9, 1664.	1.0	16
57	Polygenic risk score opportunities for early detection and prevention strategies in endometrial cancer. British Journal of Cancer, 2020, 123, 1045-1046.	2.9	7
58	Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer. Cancers, 2020, 12, 276.	1.7	18
59	The Mirena coil is a suitable treatment of early-stage endometrial cancer in obese women. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 1001-1001.	1.1	7
60	Association between genetic polymorphisms and endometrial cancer risk: a systematic review. Journal of Medical Genetics, 2020, 57, 591-600.	1.5	28
61	Prevalence and prognosis of lynch syndrome and sporadic mismatch repair deficiency in the combined PORTEC-1,-2 and -3 endometrial cancer trials. , 2020, , .		1
62	The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. PLoS Medicine, 2020, 17, e1003295.	3.9	73
63	Endometrial cancer and obesity. The Obstetrician and Gynaecologist, 2019, 21, 237-245.	0.2	23
64	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. Histopathology, 2019, 75, 813-824.	1.6	19
65	Proteomic Biomarkers for the Detection of Endometrial Cancer. Cancers, 2019, 11, 1572.	1.7	59
66	Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy. Annals of Oncology, 2019, 30, v899-v900.	0.6	15
67	Variation in the initial assessment and investigation for ovarian cancer in symptomatic women: a systematic review of international guidelines. BMC Cancer, 2019, 19, 1028.	1.1	21
68	Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting. PLoS ONE, 2019, 14, e0221419.	1.1	22
69	Top ten research priorities for detecting cancer early. Lancet Public Health, The, 2019, 4, e551.	4.7	45
70	Impact of surgical site infection (SSI) following gynaecological cancer surgery in the UK: a trainee-led multicentre audit and service evaluation. BMJ Open, 2019, 9, e024853.	0.8	14
71	Prevalence of germline pathogenic <i>BRCA1/2</i> variants in sequential epithelial ovarian cancer cases. Journal of Medical Genetics, 2019, 56, 301-307.	1.5	21
72	Optimization of Window Study Endpoints in Endometrial Cancer. Frontiers in Oncology, 2019, 9, 428.	1.3	0

#	ARTICLE	IF	CITATIONS
73	Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors. <i>Cancers</i> , 2019, 11, 653.	1.7	27
74	The proportion of endometrial cancers associated with Lynch syndrome: a systematic review of the literature and meta-analysis. <i>Genetics in Medicine</i> , 2019, 21, 2167-2180.	1.1	139
75	Cross-sectional study of HPV testing in self-sampled urine and comparison with matched vaginal and cervical samples in women attending colposcopy for the management of abnormal cervical screening. <i>BMJ Open</i> , 2019, 9, e025388.	0.8	43
76	A Micro-Costing Study of Screening for Lynch Syndrome-Associated Pathogenic Variants in an Unselected Endometrial Cancer Population: Cheap as NGS Chips?. <i>Frontiers in Oncology</i> , 2019, 9, 61.	1.3	8
77	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. <i>Genetics in Medicine</i> , 2019, 21, 2390-2400.	1.1	153
78	Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report. <i>Hereditary Cancer in Clinical Practice</i> , 2019, 17, 8.	0.6	42
79	Prognostic relevance of the molecular classification in high-risk endometrial cancer: analysis of the PORTEC-3 trial. , 2019, , .		1
80	PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2424-2432.	3.2	41
81	The impact of obesity and bariatric surgery on circulating and tissue biomarkers of endometrial cancer risk. <i>International Journal of Cancer</i> , 2019, 144, 641-650.	2.3	87
82	Population-based testing of non-mucinous epithelial ovarian cancer in Scotland. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1459-1459.	1.1	1
83	The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer. <i>Gynecologic Oncology</i> , 2018, 150, 99-105.	0.6	49
84	The vaginal microbiome and gynaecological cancer: exercise caution when considering causation. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 316-316.	1.1	6
85	A cluster randomized trial of strategies to increase uptake amongst young women invited for their first cervical screen: The STRATEGIC trial. <i>Journal of Medical Screening</i> , 2018, 25, 88-98.	1.1	20
86	The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study. <i>Gynecologic Oncology</i> , 2018, 148, 154-160.	0.6	36
87	Prevention Strategies in Endometrial Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 101.	1.8	50
88	High prevalence of metabolic syndrome in women newly diagnosed with endometrial cancer. <i>Gynecologic Oncology Reports</i> , 2018, 26, 109-110.	0.3	11
89	Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative. <i>Modern Pathology</i> , 2018, 31, 1851-1861.	2.9	35
90	The prevalence of Lynch syndrome in women with endometrial cancer: a systematic review protocol. <i>Systematic Reviews</i> , 2018, 7, 121.	2.5	15

#	ARTICLE	IF	CITATIONS
91	Targeted lung cancer screening selects individuals at high risk of cardiovascular disease. <i>Lung Cancer</i> , 2018, 124, 148-153.	0.9	27
92	Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 491-495.	0.6	71
93	Biomarkers needed to predict progestin response in endometrial cancer. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1584-1584.	1.1	18
94	Identifying High-Risk Women for Endometrial Cancer Prevention Strategies: Proposal of an Endometrial Cancer Risk Prediction Model. <i>Cancer Prevention Research</i> , 2017, 10, 1-13.	0.7	68
95	Urinary HPV testing may offer hope for cervical screening non-attenders. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1364-1364.	1.1	5
96	Homozygous germ-line mutation of the PMS2 mismatch repair gene: a unique case report of constitutional mismatch repair deficiency (CMMRD). <i>BMC Medical Genetics</i> , 2017, 18, 40.	2.1	25
97	Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A Trans PORTEC initiative. <i>Gynecologic Oncology</i> , 2017, 146, 327-333.	0.6	26
98	Optimising fertility outcomes for women with early-stage cervical cancer: when less is more. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1736-1736.	1.1	0
99	Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies. <i>Modern Pathology</i> , 2017, 30, 459-468.	2.9	53
100	Monocarboxylate Transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer. <i>BMC Clinical Pathology</i> , 2017, 17, 27.	1.8	36
101	BRCA and lynch syndrome-associated ovarian cancers behave differently. <i>Gynecologic Oncology Reports</i> , 2017, 22, 108-109.	0.3	11
102	Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions. <i>Gynecologic Oncology</i> , 2016, 143, 287-293.	0.6	77
103	Obesity and endometrial cancer: unanswered epidemiological questions. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2016, 123, 175-178.	1.1	13
104	Measuring the biological effect of presurgical metformin treatment in endometrial cancer. <i>British Journal of Cancer</i> , 2016, 114, 281-289.	2.9	75
105	Are rigid management protocols stifling innovation in cancer treatment?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2015, 122, 1432-1434.	1.1	0
106	Soy intake and endometrial cancer risk varies according to study population. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2015, 122, 311-311.	1.1	2
107	Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters. <i>British Journal of Cancer</i> , 2015, 113, 786-793.	2.9	20
108	The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia. <i>Journal of Clinical Microbiology</i> , 2015, 53, 3553-3559.	1.8	9

#	ARTICLE	IF	CITATIONS
109	Re: Prediagnosis Body Mass Index, Physical Activity, and Mortality in Endometrial Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt375-djt375.	3.0	8
110	Commentary on "Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening". <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2014, 121, 40-47.	1.1	0
111	Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications. <i>Human Reproduction Update</i> , 2014, 20, 853-868.	5.2	94
112	Prophylactic pre-operative bilateral ureteric catheters for major gynaecological surgery. <i>Archives of Gynecology and Obstetrics</i> , 2013, 288, 1061-1066.	0.8	24
113	Developing role of HPV in cervical cancer prevention. <i>BMJ, The</i> , 2013, 347, f4781-f4781.	3.0	26
114	Obesity-driven endometrial cancer: is weight loss the answer?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 791-794.	1.1	59
115	The surgical rectus sheath block for post-operative analgesia: a modern approach to an established technique. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 160, 196-200.	0.5	44
116	Global human papillomavirus vaccination: can it be cost-effective?. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2012, 119, 125-128.	1.1	1
117	Apronectomy combined with laparotomy for morbidly obese endometrial cancer patients. <i>Surgical Oncology</i> , 2011, 20, e187-e193.	0.8	4
118	The accuracy of the sentinel node procedure after excision biopsy in squamous cell carcinoma of the vulva. <i>Surgical Oncology</i> , 2010, 19, e150-e154.	0.8	17
119	Cervical cancer: problem solved? Vaccinating girls against human papillomavirus. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2010, 117, 137-142.	1.1	12
120	Gastrointestinal stromal tumour presenting as an ovarian tumour. <i>Journal of Obstetrics and Gynaecology</i> , 2010, 30, 324-325.	0.4	1
121	Uterine sarcoma: A rare cause of uterine inversion. <i>Journal of Obstetrics and Gynaecology</i> , 2009, 29, 776-778.	0.4	2
122	The management of vulval cancer. <i>Cancer Treatment Reviews</i> , 2009, 35, 533-539.	3.4	34
123	Recent advances in the treatment of advanced or recurrent endometrial cancer. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 521-532.	0.4	0